Physician profile
Stephen M Squires
NPI 1346476199
$2,325.07
in general payments reported to CMS, 2019-2025
25 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $173 · 2021: $395 · 2022: $931 · 2023: $209 · 2024: $318 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.92 | 2021-2025 | Skyrizi |
| Organogenesis INC. | $358.82 | 2021-2024 | Puraply |
| Incyte Corporation | $249.13 | 2021-2024 | Opzelura |
| Merz North America, INC. | $179.41 | 2022 | |
| Journey Medical Corporation | $119.57 | 2022 | |
| Ucb, INC. | $117.16 | 2022-2024 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $102.74 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Janssen Scientific Affairs, LLC | $93.22 | 2019 | |
| Janssen Biotech, INC. | $75.43 | 2021-2022 | |
| Biofrontera INC. | $72.60 | 2021-2022 | |
| Amgen INC. | $71.98 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $67.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $51.78 | 2022-2024 | |
| Prugen, INC. Pharmaceuticals | $42.16 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $36.65 | 2019 | |
| Sun Pharmaceutical Industries INC. | $36.54 | 2024 | |
| Pfizer INC. | $28.93 | 2021-2024 | |
| Lilly USA, LLC | $27.67 | 2024 | Taltz |
| Genzyme Corporation | $21.97 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $20.35 | 2024 | Valchlor |
| Accord Healthcare, INC. | $15.93 | 2023 | |
| Alexion Pharmaceuticals, INC. | $14.73 | 2025 | Ultomiris |
| Tactile Systems Technology INC | $14.16 | 2022 | |
| Nabriva Therapeutics, Plc | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.